Cargando…

Tegumentary leishmaniasis and coinfections other than HIV

BACKGROUND: Tegumentary leishmaniasis (TL) is a disease of skin and/or mucosal tissues caused by Leishmania parasites. TL patients may concurrently carry other pathogens, which may influence the clinical outcome of TL. METHODOLOGY AND PRINCIPAL FINDINGS: This review focuses on the frequency of TL co...

Descripción completa

Detalles Bibliográficos
Autores principales: Martínez, Dalila Y., Verdonck, Kristien, Kaye, Paul M., Adaui, Vanessa, Polman, Katja, Llanos-Cuentas, Alejandro, Dujardin, Jean-Claude, Boelaert, Marleen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5832191/
https://www.ncbi.nlm.nih.gov/pubmed/29494584
http://dx.doi.org/10.1371/journal.pntd.0006125
_version_ 1783303282154799104
author Martínez, Dalila Y.
Verdonck, Kristien
Kaye, Paul M.
Adaui, Vanessa
Polman, Katja
Llanos-Cuentas, Alejandro
Dujardin, Jean-Claude
Boelaert, Marleen
author_facet Martínez, Dalila Y.
Verdonck, Kristien
Kaye, Paul M.
Adaui, Vanessa
Polman, Katja
Llanos-Cuentas, Alejandro
Dujardin, Jean-Claude
Boelaert, Marleen
author_sort Martínez, Dalila Y.
collection PubMed
description BACKGROUND: Tegumentary leishmaniasis (TL) is a disease of skin and/or mucosal tissues caused by Leishmania parasites. TL patients may concurrently carry other pathogens, which may influence the clinical outcome of TL. METHODOLOGY AND PRINCIPAL FINDINGS: This review focuses on the frequency of TL coinfections in human populations, interactions between Leishmania and other pathogens in animal models and human subjects, and implications of TL coinfections for clinical practice. For the purpose of this review, TL is defined as all forms of cutaneous (localised, disseminated, or diffuse) and mucocutaneous leishmaniasis. Human immunodeficiency virus (HIV) coinfection, superinfection with skin bacteria, and skin manifestations of visceral leishmaniasis are not included. We searched MEDLINE and other databases and included 73 records: 21 experimental studies in animals and 52 studies about human subjects (mainly cross-sectional and case studies). Several reports describe the frequency of Trypanosoma cruzi coinfection in TL patients in Argentina (about 41%) and the frequency of helminthiasis in TL patients in Brazil (15% to 88%). Different hypotheses have been explored about mechanisms of interaction between different microorganisms, but no clear answers emerge. Such interactions may involve innate immunity coupled with regulatory networks that affect quality and quantity of acquired immune responses. Diagnostic problems may occur when concurrent infections cause similar lesions (e.g., TL and leprosy), when different pathogens are present in the same lesions (e.g., Leishmania and Sporothrix schenckii), or when similarities between phylogenetically close pathogens affect accuracy of diagnostic tests (e.g., serology for leishmaniasis and Chagas disease). Some coinfections (e.g., helminthiasis) appear to reduce the effectiveness of antileishmanial treatment, and drug combinations may cause cumulative adverse effects. CONCLUSIONS AND SIGNIFICANCE: In patients with TL, coinfection is frequent, it can lead to diagnostic errors and delays, and it can influence the effectiveness and safety of treatment. More research is needed to unravel how coinfections interfere with the pathogenesis of TL.
format Online
Article
Text
id pubmed-5832191
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-58321912018-03-19 Tegumentary leishmaniasis and coinfections other than HIV Martínez, Dalila Y. Verdonck, Kristien Kaye, Paul M. Adaui, Vanessa Polman, Katja Llanos-Cuentas, Alejandro Dujardin, Jean-Claude Boelaert, Marleen PLoS Negl Trop Dis Review BACKGROUND: Tegumentary leishmaniasis (TL) is a disease of skin and/or mucosal tissues caused by Leishmania parasites. TL patients may concurrently carry other pathogens, which may influence the clinical outcome of TL. METHODOLOGY AND PRINCIPAL FINDINGS: This review focuses on the frequency of TL coinfections in human populations, interactions between Leishmania and other pathogens in animal models and human subjects, and implications of TL coinfections for clinical practice. For the purpose of this review, TL is defined as all forms of cutaneous (localised, disseminated, or diffuse) and mucocutaneous leishmaniasis. Human immunodeficiency virus (HIV) coinfection, superinfection with skin bacteria, and skin manifestations of visceral leishmaniasis are not included. We searched MEDLINE and other databases and included 73 records: 21 experimental studies in animals and 52 studies about human subjects (mainly cross-sectional and case studies). Several reports describe the frequency of Trypanosoma cruzi coinfection in TL patients in Argentina (about 41%) and the frequency of helminthiasis in TL patients in Brazil (15% to 88%). Different hypotheses have been explored about mechanisms of interaction between different microorganisms, but no clear answers emerge. Such interactions may involve innate immunity coupled with regulatory networks that affect quality and quantity of acquired immune responses. Diagnostic problems may occur when concurrent infections cause similar lesions (e.g., TL and leprosy), when different pathogens are present in the same lesions (e.g., Leishmania and Sporothrix schenckii), or when similarities between phylogenetically close pathogens affect accuracy of diagnostic tests (e.g., serology for leishmaniasis and Chagas disease). Some coinfections (e.g., helminthiasis) appear to reduce the effectiveness of antileishmanial treatment, and drug combinations may cause cumulative adverse effects. CONCLUSIONS AND SIGNIFICANCE: In patients with TL, coinfection is frequent, it can lead to diagnostic errors and delays, and it can influence the effectiveness and safety of treatment. More research is needed to unravel how coinfections interfere with the pathogenesis of TL. Public Library of Science 2018-03-01 /pmc/articles/PMC5832191/ /pubmed/29494584 http://dx.doi.org/10.1371/journal.pntd.0006125 Text en © 2018 Martínez et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Review
Martínez, Dalila Y.
Verdonck, Kristien
Kaye, Paul M.
Adaui, Vanessa
Polman, Katja
Llanos-Cuentas, Alejandro
Dujardin, Jean-Claude
Boelaert, Marleen
Tegumentary leishmaniasis and coinfections other than HIV
title Tegumentary leishmaniasis and coinfections other than HIV
title_full Tegumentary leishmaniasis and coinfections other than HIV
title_fullStr Tegumentary leishmaniasis and coinfections other than HIV
title_full_unstemmed Tegumentary leishmaniasis and coinfections other than HIV
title_short Tegumentary leishmaniasis and coinfections other than HIV
title_sort tegumentary leishmaniasis and coinfections other than hiv
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5832191/
https://www.ncbi.nlm.nih.gov/pubmed/29494584
http://dx.doi.org/10.1371/journal.pntd.0006125
work_keys_str_mv AT martinezdalilay tegumentaryleishmaniasisandcoinfectionsotherthanhiv
AT verdonckkristien tegumentaryleishmaniasisandcoinfectionsotherthanhiv
AT kayepaulm tegumentaryleishmaniasisandcoinfectionsotherthanhiv
AT adauivanessa tegumentaryleishmaniasisandcoinfectionsotherthanhiv
AT polmankatja tegumentaryleishmaniasisandcoinfectionsotherthanhiv
AT llanoscuentasalejandro tegumentaryleishmaniasisandcoinfectionsotherthanhiv
AT dujardinjeanclaude tegumentaryleishmaniasisandcoinfectionsotherthanhiv
AT boelaertmarleen tegumentaryleishmaniasisandcoinfectionsotherthanhiv